Clinical and biological features of patients
| . | Fusion class, no. of patients . | ||||
|---|---|---|---|---|---|
| Negative . | NUTM1 class . | PAX5 class . | Other . | Total . | |
| Sex | |||||
| Male | 4 | 2 | 2 | 1 | 9 |
| Female | 4 | 7 | 4 | 6 | 21 |
| Age at diagnosis, mo | |||||
| 0 to <3 | 1 | 3 | 0 | 0 | 4 |
| 3 to <6 | 0 | 1 | 0 | 1 | 2 |
| 6 to <9 | 0 | 2 | 1 | 2 | 5 |
| 9 to <12 | 7 | 3 | 5 | 4 | 19 |
| WBC count, ×109/L | |||||
| ≤100 | 8 | 6 | 5 | 4 | 23 |
| 100-300 | 0 | 2 | 1 | 3 | 6 |
| ≥300 | 0 | 1 | 0 | 0 | 1 |
| Immunophenotype | |||||
| CD10− | 0 | 1 | 0 | 1 | 2 |
| CD10+ | 8 | 8 | 6 | 6 | 28 |
| Prednisone response | |||||
| PGR | 6 | 8 | 5 | 7 | 26 |
| PPR | 1 | 1 | 1 | 0 | 3 |
| NK | 1 | 0 | 0 | 0 | 1 |
| MRD at EOI, ×10−4* | |||||
| Negative | 4 (0) | 2 (0) | 0 | 1 (0) | 7 (0) |
| <5 | 0 | 5 (0) | 2 (1) | 4 (2) | 11 (3) |
| ≥5 | 0 | 0 | 2 (2) | 1 (1) | 3 (3) |
| Total | 8 | 9 | 6 | 7 | 30 |
| . | Fusion class, no. of patients . | ||||
|---|---|---|---|---|---|
| Negative . | NUTM1 class . | PAX5 class . | Other . | Total . | |
| Sex | |||||
| Male | 4 | 2 | 2 | 1 | 9 |
| Female | 4 | 7 | 4 | 6 | 21 |
| Age at diagnosis, mo | |||||
| 0 to <3 | 1 | 3 | 0 | 0 | 4 |
| 3 to <6 | 0 | 1 | 0 | 1 | 2 |
| 6 to <9 | 0 | 2 | 1 | 2 | 5 |
| 9 to <12 | 7 | 3 | 5 | 4 | 19 |
| WBC count, ×109/L | |||||
| ≤100 | 8 | 6 | 5 | 4 | 23 |
| 100-300 | 0 | 2 | 1 | 3 | 6 |
| ≥300 | 0 | 1 | 0 | 0 | 1 |
| Immunophenotype | |||||
| CD10− | 0 | 1 | 0 | 1 | 2 |
| CD10+ | 8 | 8 | 6 | 6 | 28 |
| Prednisone response | |||||
| PGR | 6 | 8 | 5 | 7 | 26 |
| PPR | 1 | 1 | 1 | 0 | 3 |
| NK | 1 | 0 | 0 | 0 | 1 |
| MRD at EOI, ×10−4* | |||||
| Negative | 4 (0) | 2 (0) | 0 | 1 (0) | 7 (0) |
| <5 | 0 | 5 (0) | 2 (1) | 4 (2) | 11 (3) |
| ≥5 | 0 | 0 | 2 (2) | 1 (1) | 3 (3) |
| Total | 8 | 9 | 6 | 7 | 30 |
EOI, end of induction therapy; NK, not known; PGR, prednisone good responder; PPR, prednisone poor responder; WBC, white blood cell.
Values in parentheses indicate no. of relapses. MRD data were available for 21 patients.